Radiation Therapy for Wilms Tumor | NYU Langone Health
NYU Langone doctors sometimes use low-dose radiation therapy to treat children who have a Wilms tumor.
Radioactive Iodine Ablation for Hyperthyroidism | NYU Langone Health
NYU Langone endocrinologists may use radioactive iodine ablation to treat hyperthyroidism.
Radioactive Iodine Therapy for Thyroid Nodules & Cancers | NYU Langone Health
NYU Langone doctors may use radioactive iodine therapy to manage some toxic nodules and thyroid cancers.
Radiofrequency Ablation for Neck Pain | NYU Langone Health
Doctors at NYU Langone may recommend radiofrequency ablation to relieve neck pain.
Radiosurgery & Radiation Therapy for Pituitary Tumors | NYU Langone Health
NYU Langone doctors may use radiosurgery or radiation therapy to manage some pituitary tumors.
Ralinepag -ROR-PH-301 (APD811-301) - A Phase 3 randomized double-blind placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH
Site for Phase 3 studies evaluating the efficacy and safety of ralinepag in patients with WHO Group 1 pulmonary arterial hypertension
Randomized Clinical Evaluation of the AccuCinch Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
The purpose of this research study is to assess the safety and effectiveness of the AccuCinch Ventricular Restoration System and compare it to standardized heart failure medications.The AccuCinch Ventricular Restoration System is an investigational (experimental) device intended to treat patients who are experiencing symptoms of heart failure due to a dilated left ventricle (heart chamber that pumps blood).
Randomized Controlled Open-Label Parallel Group Multi-Center Prospective Phase 4 Study Comparing the Efficacy of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2 3 and 4 Pressure Injuries
This post-marketing study is being performed to assess the effectiveness of Altrazeal® Transforming Powder Dressing (“Altrazeal®” or “TPD”) manufactured by ULURU Inc. in patients with pressure injuries (sometimes also referred to as pressure sores or decubitus ulcers) compared to the current Standard of Care (SOC) therapies. TPD is manufactured, marketed, and used in the United States of America (US). ULURU Inc. is registered with the US Food and Drug Administration (FDA) and Altrazeal® is listed as a Class I 510(k) exempt medical device: “dressing, wound, hydrogel without drug and/or biologic.” (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=410757&lpcd=NAE) Under the supervision of a health care professional, TPD may be used in surgical, acute or chronic wounds including pressure injuries.Objectives:Primary: To compare the efficacy of TPD in reducing primary dressing changes in the treatment of non-infected Stage 2, 3 and 4 pressure injuries (PrIs).Secondary: Evaluate: 1) wound healing trajectories2) safety in the form of adverse events3) subject pain for sensate patientsExploratory: Evaluate: 1) resource utilization of TPD relative to SOC2) cost-effectiveness of TPD versus SOC3) budget impact analysis of adopting TPD4) wound quality of life5) research subject satisfaction6) other ad-hoc analyses as warranted
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus (EXPAND)
The purpose of this clinical research study is to learn more about the use of the study drug, maralixibat, for the treatment of cholestatic pruritus (itch due to liver disease).
Randomized Double-Blind Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
In this clinical trial, we are testing a drug called glial cell line-derived neurotrophic factor (GDNF) gene transfer to see if it helps people with Multiple System Atrophy (MSA). GDNF gene is delivered to a part of the brain involved in MSA. This study will evaluate the safety of this study drug, and see whether it can improve the course of MSA.